Send to a Friend Font Size: Increase Decrease

NTHI and MRK Related Headlines

Mar 4, 2026 08:00AM NeOnc Technologies sets phase 2 dose for brain cancer drug NEO212
Mar 4, 2026 08:00AM NeOnc Technologies Reports Phase 1 Dose-Escalation Results for Dosing and Toxicity and Determination of Recommended Phase 2 Dose for Oral NEO212; Management to Host KOL Conference Call Today at 9 a.m.

NTHI and MRK Related Press Releases

Mar 4, 2026 08:00AM NeOnc Technologies Reports Phase 1 Dose-Escalation Results for Dosing and Toxicity and Determination of Recommended Phase 2 Dose for Oral NEO212; Management to Host KOL Conference Call Today at 9 a.m.

NTHI and MRK Related SEC Filings